NextCure Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

NextCure şirketinin toplam hissedar öz sermayesi $26.7M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $38.0M ve $11.3M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$29.74m
Eşitlik	US$26.72m
Toplam yükümlülükler	US$11.26m
Toplam varlıklar	US$37.98m

Son finansal sağlık güncellemeleri

Analiz Makalesi • Oct 18

Recent updates

Analiz Makalesi • Oct 18

Here's Why NextCure (NASDAQ:NXTC) Must Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analiz Makalesi • Nov 13

Here's Why We're Watching NextCure's (NASDAQ:NXTC) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analiz Makalesi • Jul 17

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analiz Makalesi • Mar 23

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analiz Makalesi • Dec 09

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analiz Makalesi • Aug 23

Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analiz Makalesi • May 10

Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Nov 22

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analiz Makalesi • Aug 09

Estimating The Intrinsic Value Of NextCure, Inc. (NASDAQ:NXTC)

How far off is NextCure, Inc. ( NASDAQ:NXTC ) from its intrinsic value? Using the most recent financial data, we'll...

Seeking Alpha • Aug 04

NextCure GAAP EPS of -$0.59

NextCure press release (NASDAQ:NXTC): Q2 GAAP EPS of -$0.59. $292.4 million in cash, cash equivalents and investments as of June 30, 2022, providing expected cash runway into Q4 2024

Analiz Makalesi • May 02

We're Not Very Worried About NextCure's (NASDAQ:NXTC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Seeking Alpha • Sep 29

NextCure: Large Upside With Downside Protected By Cash Pile

The stock is left for dead, trading significantly below cash which creates a margin of safety. Significant data on all 3 drugs is due in the next 9 months. If one of the 3 readouts is positive, this could become an instant multibagger.

Analiz Makalesi • Feb 12

Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like

Every investor in NextCure, Inc. ( NASDAQ:NXTC ) should be aware of the most powerful shareholder groups. Generally...

Analiz Makalesi • Jan 08

NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares

As every investor would know, you don't hit a homerun every time you swing. But serious investors should think long and...

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: NXTC 'nin kısa vadeli varlıkları ( $31.7M ) kısa vadeli yükümlülüklerini ( $6.9M ) aşıyor.

Uzun Vadeli Yükümlülükler: NXTC şirketinin kısa vadeli varlıkları ( $31.7M ) uzun vadeli yükümlülüklerini ( $4.4M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: NXTC borçsuzdur.

Borcun Azaltılması: NXTC şirketinin 5 yıl önce borç/öz sermaye oranı 1.1% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: NXTC şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: Serbest nakit akışı her yıl % 1.9 oranında tarihsel oranda büyümeye devam ederse NXTC un bir yıldan az nakit akışı süresi vardır.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/06/11 18:55
Gün Sonu Hisse Fiyatı	2026/06/11 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

NextCure, Inc. 10 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Aydin Huseynov	Benchmark Company
Alec Stranahan	BofA Global Research
Reni Benjamin	Citizens JMP Securities, LLC

NextCure Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why NextCure (NASDAQ:NXTC) Must Use Its Cash Wisely

NextCure Receives Nasdaq Non-Compliance Letter Regarding Minimum Bid Requirement

Here's Why We're Watching NextCure's (NASDAQ:NXTC) Cash Burn Situation

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Recent updates

New major risk - Market cap size

NextCure, Inc. Presents Positive SIM0505 Phase 1 Dose Escalation Data In Patients With Gynecologic Cancers At ASCO

New major risk - Share price stability

New major risk - Revenue and earnings growth

New major risk - Financial position

Nextcure, Inc. and Simcere Zaiming Pharmaceutical Co., Ltd. Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers

NextCure, Inc., Annual General Meeting, Jun 18, 2026

New minor risk - Share price stability

NextCure Inc Receives Fast Track Designation For SIM0505 In Ovarian Cancer

NextCure Inc and Simcere Zaiming Pharmaceutical Co Ltd Abstract for SIM0505 is Accepted for ASCO 2026

New minor risk - Financial position

Nextcure, Inc. Provides Updates for Its Two Antibody Drug Conjugate Programs

NextCure, Inc. has filed a Follow-on Equity Offering in the amount of $14.5 million.

New major risk - Shareholder dilution

NextCure, Inc. announced that it has received $21.498209 million in funding from Ikarian Capital, LLC, Squadron Capital Management Llc, Affinity Asset Advisors, LLC, Exome Asset Management LLC

NextCure, Inc. announced that it expects to receive $21.500024 million in funding from Ikarian Capital, LLC, Squadron Capital Management Llc, Affinity Asset Advisors, LLC, Exome Asset Management LLC and other investors.

Here's Why NextCure (NASDAQ:NXTC) Must Use Its Cash Wisely

New minor risk - Share price stability

Nextcure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of Sim0505 (Cdh6 Adc) into the United States

New major risk - Financial position

NextCure, Inc. Announces the Presentation of New Preclinical Data in A Well-Established Model of Osteogenesis Imperfecta

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

New minor risk - Share price stability

NextCure, Inc., Annual General Meeting, Jun 20, 2025

New major risk - Market cap size

New major risk - Revenue and earnings growth

NextCure Receives Nasdaq Non-Compliance Letter Regarding Minimum Bid Requirement

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 as Therapeutic for Treating Multiple Cancers

NextCure, Inc. Announces Acceptance of IND Application for LNCB74

NextCure, Inc. Announces the Presentation of Preclinical Data Demonstrating That Treatment with Nc605, A Novel Anti-Siglec-15 (S15) Antibody

Here's Why We're Watching NextCure's (NASDAQ:NXTC) Cash Burn Situation

NextCure, Inc. Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo At Society for Immunotherapy of Cancer Annual Meeting

Insufficient new directors

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

NextCure, Inc. Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

New major risk - Revenue and earnings growth

NextCure, Inc., Annual General Meeting, Jun 20, 2024

NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024

NextCure, Inc. Appoints Rakesh Dixit to Scientific Advisory Board

New major risk - Revenue and earnings growth

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

Nextcure, Inc. Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

Nextcure, Inc. Provides Year-End Clinical Pipeline Updates

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

NextCure, Inc. Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

NextCure, Inc. Announces Presentation of New Preclinical Data Demonstrate Treatment with NC605

NextCure, Inc. Presents Preclinical Data on Nc181, A Novel Therapeutic Candidate Targeting Apoe4, for the Treatment of Alzheimer's Disease

Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?

Price target decreased by 25% to US$4.33

NextCure, Inc. Announces Resignation of Garry A. Nicholson as from the Board of Directors

Price target decreased by 25% to US$4.33

Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?

Price target increased to US$6.67

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Price target decreased to US$5.80

Price target decreased to US$6.25

Estimating The Intrinsic Value Of NextCure, Inc. (NASDAQ:NXTC)

Price target increased to US$14.14

NextCure GAAP EPS of -$0.59

High number of new directors

Now 23% undervalued after recent price drop

We're Not Very Worried About NextCure's (NASDAQ:NXTC) Cash Burn Rate

High number of new directors

Price target decreased to US$16.75

High number of new directors

Independent Director Xiaoxing Xu has left the company

NextCure: Large Upside With Downside Protected By Cash Pile

Independent Director has left the company